

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Stephan Duda

Page 1/3

Thursday, January 29, 2015

MAIN ARENA 1

08:00 – 09:30

Innovative approaches and hot topics in endovascular interventions

CHAIRMAN:

Lawrence Garcia

MODERATOR:

Koen Deloose

Josef Tacke

Michael Lichtenberg

William Gray

Sigrid Nikol

Lieven Maene

Erich Minar

08:00 – 08:05

Does stent design influence the results of SFA stenting?

Koen Deloose

08:05 – 08:10

New approaches for drug-eluting stents: The NitiDES programme

Dierk Scheinert

08:10 – 08:25

Recorded case via satellite from Münster

08:25 – 08:30

Results from the Freeway Stent study

Josef Tacke

08:30 – 08:35

ILLUMINATE Direct: 12 months results with direct DCB use in femoropopliteal arteries

Stephan Duda

08:35 – 08:40

Next generation DCB coating—the EffPac-trial

Sebastian Sixt

08:40 – 09:00

Live case transmission from Bad Krozingen

09:00 – 09:05

RELINE-trial: 24 months results with the Viabahn vs. PTA for in-stent restenosis

Koen Deloose

09:05 – 09:10

The role of DCB for SFA-ISR

Yann Gouëffic

09:10 – 09:15

First experience with DCB in AV-fistulas

Stephan Duda

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Stephan Duda

Page 2/3

Thursday, January 29, 2015

- | | |
|---------------|--|
| 09:15 – 09:20 | The utility of carbon-dioxide angiography in peripheral interventions
Ulf Teichgräber |
| 09:20 – 09:25 | Using ARROW GPSCath to protect wire placement, reduce fluoroscopy while minimizing contrast
Michael Lichtenberg |
| 09:25 – 09:30 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Stephan Duda

Page 3/3

Thursday, January 29, 2015

DISCUSSION FORUM

12:30 – 13:30

The great debate: Are all DCB equal?

CHAIRMAN:

Michael Jaff
Dierk Scheinert

DISCUSSANT:

Gunnar Tepe
Renu Virmani

Stephan Duda

Marianne Brodmann

12:30 – 12:37

There are clear differences in DCB outcomes in the SFA for various coatings – DCB are not equal!

Gunnar Tepe

12:37 – 12:44

Lacking head-to-head trials comparing different DCB studies is comparing apples and oranges – Results have been substantially affected by trial design

12:44 – 12:51

The relevance of Paclitaxel dose and coating for efficacy and safety

Renu Virmani

12:51 – 12:58

Whats next to come in the drug delivery space: Ongoing DCB programmes

Stephan Duda

12:58 – 13:05

Lessons learned from INPACT.Deep and why we should stay away from DCB for BTK interventions

Erich Minar

13:05 – 13:12

DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are continuing

Marianne Brodmann

13:12 – 13:30

Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.